Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Astrocytoma, Grade IV: early-phase trial registry
4 of 5 indexed Astrocytoma, Grade IV trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Astrocytoma, Grade IV: 5 US clinical trials tracked, 4 recruiting.
Astrocytoma, Grade IV is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is James Markert, MD, running 1 of these trials.
Enrollment posture brief
Registry condition astrocytoma-grade-iv
OPEN 4 | RECR 80% | LATE 1 | EARLY 3 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Astrocytoma, Grade IV lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Astrocytoma, Grade IV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Astrocytoma, Grade IV is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Astrocytoma, Grade IV research.
James Markert, MD accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Astrocytoma, Grade IV trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Astrocytoma, Grade IV research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Jasper Gerritsen
NCT06118723
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Nuvation Bio
NCT05303519
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
NCT06161974
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Mayo Clinic
NCT05789394
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
James Markert, MD
NCT06614855
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Astrocytoma, Grade IV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Astrocytoma, Grade IV trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Astrocytoma, Grade IV page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Astrocytoma, Grade IV trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- James Markert, MD sponsors the most Astrocytoma, Grade IV trials on record, review their full trial history before evaluating a specific study. See James Markert, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Astrocytoma, Grade IV condition card totals 5 registered trials; most-linked intervention C134; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.